Pulmonary hypertension affects approximately 1% of the global population, with prevalence rising to nearly 10% of adults over age 65. Left heart disease and lung disease (WHO Groups 2 and 3) account for the majority of cases in the Medicare population. PAH-specific therapies used for Group 1 disease should not automatically be applied to Groups 2 or 3. Many are not recommended—and some may be harmful—in pulmonary hypertension caused by left-heart or lung disease. Treatment must be group-specific, with selected exceptions such as consideration of inhaled trepostinil in pulmonary hypertension associated with interstitial lung disease. Precise recognition, hemodynamic confirmation by right heart catheterization, and coding specificity are among the highest-value clinical actions a primary care team can take.
AAVBC's Pulmonary Hypertension Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering WHO group classification, hemodynamic diagnostic thresholds, ICD-10 and HCC/RAF V28 coding specificity, MEAT documentation standards, the four-stratum risk stratification model, therapy escalation criteria, comorbidity screening, and referral timing. Grounded in current ESC/ERS 2022 pulmonary hypertension guidelines, this guide supports consistent, individualized clinical decision-making, helping care teams classify PH by WHO group accurately, document clinical complexity completely, and coordinate specialist referral with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of pulmonary hypertension — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Pulmonary hypertension affects approximately 1% of the global population, with prevalence rising to nearly 10% of adults over age 65. Left heart disease and lung disease (WHO Groups 2 and 3) account for the majority of cases in the Medicare population. PAH-specific therapies used for Group 1 disease should not automatically be applied to Groups 2 or 3. Many are not recommended—and some may be harmful—in pulmonary hypertension caused by left-heart or lung disease. Treatment must be group-specific, with selected exceptions such as consideration of inhaled trepostinil in pulmonary hypertension associated with interstitial lung disease. Precise recognition, hemodynamic confirmation by right heart catheterization, and coding specificity are among the highest-value clinical actions a primary care team can take.
AAVBC's Pulmonary Hypertension Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering WHO group classification, hemodynamic diagnostic thresholds, ICD-10 and HCC/RAF V28 coding specificity, MEAT documentation standards, the four-stratum risk stratification model, therapy escalation criteria, comorbidity screening, and referral timing. Grounded in current ESC/ERS 2022 pulmonary hypertension guidelines, this guide supports consistent, individualized clinical decision-making, helping care teams classify PH by WHO group accurately, document clinical complexity completely, and coordinate specialist referral with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of pulmonary hypertension — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
